Low serum concentrations of moxifloxacin, prothionamide, and cycloserine on sputum conversion in multi-drug resistant TB

Yonsei Medical Journal

Volumn 56, Issue 4, 2015, Pages 961-967

  Lee, Seung Heon ^a   Seo, Kyung Ah ^b   Lee, Young Min ^b   Lee, Hyun Kyung ^b   Kim, Je Hyeong ^a   Shin, Chol ^a   Ghim, Jong Ryul ^b   Shin, Jae Gook ^b   Kim, Dong Hyun ^b  

^a Korea University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Cycloserine; Drug monitoring; Moxifloxacin; Multidrug resistance; Prothionamide; Tuberculosis

Indexed keywords

CYCLOSERINE; MOXIFLOXACIN; PROTIONAMIDE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER TOXICITY; MALE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; RETROSPECTIVE STUDY; SKIN DISEASE; TANDEM MASS SPECTROMETRY; THORAX RADIOGRAPHY; BLOOD; MEDICATION COMPLIANCE; MICROBIOLOGY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; AGED; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSERINE; FLUOROQUINOLONES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PROTHIONAMIDE; RETROSPECTIVE STUDIES; SPUTUM; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84931073781     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2015.56.4.961     Document Type: Article

References (23)

1. World Health Organization. Global tuberculosis control: WHO report 2011. Geneva: World Health Organization; 2011.
2. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-6.
3. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:113-9.
4. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-5.
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. Geneva: World Health Organization; 2011.
6. Cremades R, Rodríguez JC, García-Pachón E, Galiana A, Ruiz-García M, López P, et al. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother 2011;66: 2281-3.
7. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
8. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
9. Peloquin CA. Therapeutic drug monitoring in the treatment of tu berculosis. Drugs 2002;62:2169-83.
10. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50:1170-7.
11. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005;41:461-9.
12. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, van der Meer JW, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002;6:497-502.
13. Li J, Burzynski JN, Lee YA, Berg D, Driver CR, Ridzon R, et al. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 2004;126:1770-6.
14. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40:1481-91.
15. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-83.
16. U.S. National Tuberculosis Association. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association; 1961.
17. Alffenaar JW, van Altena R, Bökkerink HJ, Luijckx GJ, van Soolingen D, Aarnoutse RE, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009;49:1080-2.
18. Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. Ther Drug Monit 1998;20: 539-42.
19. Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA. Tuberc Res Treat 2013;2013:129723.
20. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012;55:169-77.
21. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.
22. Wallis RS, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One 2013;8:e71116.
23. Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2013;188:858-64.